RNA, U1 small nuclear 151, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-151P profile across patient tissues and cancer cell-line models. RNU1-151P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNU1-151P is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RNU1-151P RNA expression shows 6,596 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where RNU1-151P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-151P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-151P survival associations across molecular data types. RNU1-151P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-151P RNA expression–survival associations across cancer types. High RNU1-151P expression shows unfavorable associations in BLCA, READ, THYM and LUSC, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNU1-151P RNA expression.
This table summarizes RNU1-151P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-151P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-151P shows lower tumor expression in ESCA and STAD and higher tumor expression in KIRC. The KIRC box plot shows higher RNU1-151P RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .011).
This table shows molecular features associated with RNU1-151P in patient tissues and cancer cell lines. In patient samples, RNU1-151P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
